Dublin, Oct. 09, 2024 (GLOBE NEWSWIRE) — The “Antibody Drug Conjugates Market Report by Component, Target, Application, End-user, and Region 2024-2032” report has been added to ResearchAndMarkets.com’s offering.
The global antibody drug conjugates market size reached US$ 7.8 Billion in 2023. Looking forward, the market is expected to reach US$ 43.7 Billion by 2032, exhibiting a growth rate (CAGR) of 21.1% during 2023-2032.
Due to sedentary lifestyles and the rising number of individuals who smoke and drink regularly, there is an increase in the prevalence of cancer around the world. This, in confluence with the escalating demand for cost-effective and successful cancer treatments, represents one of the key factors bolstering the growth of the market. Apart from this, the existing linkers often release payloads nonspecifically and lead to off-target toxicity, which severely affects the development of ADCs. As a result, leading players are continuously funding their research and development (R&D) projects to optimize the existing chemical triggers and develop novel chemical triggers to generate highly selective linkers.
They are also coming up with novel linker-antibody attachments to produce stable and homogenous ADCs and additional linker-payload attachments to allow the expansion of payloads. Moreover, they are focusing on improving the absorption, distribution, metabolism, and excretion, which is creating a favorable market outlook. Other major factors, including considerably improving healthcare infrastructure, increasing awareness about therapies available for cancer treatments, and the introduction of cleavable linker technology, are anticipated to propel the market growth.
This report provides an analysis of the key trends in each sub-segment of the global antibody drug conjugates market report, along with forecasts at the global, regional and country level from 2024-2032. The report has categorized the market based on component, target, application and end-user.
Breakup by Component:
- Monoclonal Antibodies
- Linker
- Cytotoxic Agent
- Others
Breakup by Target:
- Antibody-Protein Toxin Conjugates
- Antibody-Chelated Radionuclide Conjugates
- Antibody-Small-Molecule Drug Conjugates
- Antibody-Enzyme Conjugates
Breakup by Application:
- Lymphoma
- Ovarian Cancer
- Lung Cancer
- Breast Cancer
- Brain Tumor
- Others
Breakup by End-user:
- Hospitals
- Specialized Cancer Centers
- Academic Research Institutes
- Biotechnology Companies
- Others
Breakup by Region:
- North America
- Asia-Pacific
- Europe
- Latin America
- Middle East and Africa
Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players being:
- ADC Therapeutics SA
- Astellas Pharma Inc.
- AstraZeneca PLC
- Celldex Therapeutics Inc.
- F. Hoffmann-La Roche AG
- Gilead Sciences Inc.
- GlaxoSmithKline PLC
- ImmunoGen Inc.
- Pfizer Inc.
- Sanofi S.A.
- Seagen Inc.
- Sorrento Therapeutics Inc.
- Takeda Pharmaceutical Company Ltd.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 141 |
| Forecast Period | 2023-2032 |
| Estimated Market Value (USD) in 2023 | $7.8 Billion |
| Forecasted Market Value (USD) by 2032 | $43.7 Billion |
| Compound Annual Growth Rate | 21.1% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/azfdln
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Antibody Drug Conjugates Market
